CLPT vs. CDRE, TNDM, INMD, LQDA, KMTS, BLFS, MDXG, ESTA, FNA, and RXST
Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Cadre (CDRE), Tandem Diabetes Care (TNDM), InMode (INMD), Liquidia (LQDA), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Paragon 28 (FNA), and RxSight (RXST). These companies are all part of the "medical equipment" industry.
ClearPoint Neuro vs.
ClearPoint Neuro (NASDAQ:CLPT) and Cadre (NYSE:CDRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation, profitability and community ranking.
30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 6.1% of ClearPoint Neuro shares are held by insiders. Comparatively, 37.0% of Cadre shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
ClearPoint Neuro has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
ClearPoint Neuro currently has a consensus target price of $25.00, indicating a potential upside of 100.24%. Cadre has a consensus target price of $37.00, indicating a potential upside of 21.41%. Given ClearPoint Neuro's higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Cadre.
In the previous week, Cadre had 8 more articles in the media than ClearPoint Neuro. MarketBeat recorded 9 mentions for Cadre and 1 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 1.89 beat Cadre's score of 0.75 indicating that ClearPoint Neuro is being referred to more favorably in the media.
Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
Cadre has a net margin of 6.34% compared to ClearPoint Neuro's net margin of -59.64%. Cadre's return on equity of 12.88% beat ClearPoint Neuro's return on equity.
ClearPoint Neuro received 8 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 88.89% of users gave ClearPoint Neuro an outperform vote while only 55.17% of users gave Cadre an outperform vote.
Summary
Cadre beats ClearPoint Neuro on 11 of the 17 factors compared between the two stocks.
Get ClearPoint Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearPoint Neuro Competitors List
Related Companies and Tools
This page (NASDAQ:CLPT) was last updated on 3/27/2025 by MarketBeat.com Staff
